| Patient | Sugar Ray Robinson |
|---|---|
| Date of birth | 1921-05-03 |
| Identifiers | MRN HR-BX003-SYN-TD; SSN (made up) 000-03-9318 |
| Document date | 1984-09-22 |
| Author | Langston Pryce-Okonjo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eleven-week review: donepezil, diabetes, hearing aids and day program. [S]
Sugar Ray Robinson returns eleven weeks after intake with his care partner, two weeks after his preventive visit. He has taken donepezil 5 mg at bedtime for five weeks without nausea, diarrhea or dizziness. Off glipizide, his home glucose readings run 120 to 170 mg/dL with no low readings. The hearing aids help most in conversation. He started the adult day program two days a week and likes the exercise group. The dilated eye examination booked after intake was missed: the clinic called the day before, but nobody at home remembered on the morning, and he no longer drives himself. He would like his Tdap today. [S]
| Element | Detail |
|---|---|
| Donepezil | 5 mg for five weeks; no side effects |
| Hemoglobin A1c | 6.9%, from 6.4% |
| Home glucose | 120 to 170 mg/dL; no lows |
| Hearing aids | Worn daily |
| Eye examination | Missed |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea, diarrhea or weight loss |
| Cardiovascular | Negative | No dizziness or fainting |
| Neurological | Positive | Memory loss unchanged; no falls |
| Psychiatric | Negative | Mood good; enjoys the day program |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 1982-03-01 | active | S |
| Glipizide 5 mg oral tablet, one tablet before breakfast | One tablet before breakfast | Oral route | 1983-01-15 to 1984-08-18 | completed | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1981-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1982-03-01 | active | S |
| Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counter | One capsule at bedtime | Oral route | 1983-10-01 to 1984-07-07 | stopped | S |
| Donepezil 5 mg oral tablet, one tablet at bedtime | One tablet at bedtime | Oral route | 1984-08-18 to 1984-09-22 | completed | S |
| Donepezil 10 mg oral tablet, one tablet at bedtime | One tablet at bedtime | Oral route | 1984-09-22 to 1984-10-01 | stopped | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1984-09-22 | Body height | 180 | cm | S |
| 1984-09-22 | Body weight | 76.2 | kg | S |
| 1984-09-22 | Body mass index (BMI) [Ratio] | 23.5 | kg/m2 | S |
| 1984-09-22 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1984-09-22 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1984-09-22 | Heart rate | 64 | /min | S |
| 1984-09-22 | Respiratory rate | 14 | /min | S |
| 1984-09-22 | Body temperature | 36.6 | Cel | S |
| 1984-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1984-09-22 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.9 | % | <=5.6% | High | S |
Vital signs recorded on 1984-09-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 128/76; pulse 64 and regular; weight 76.2 kg |
| Mental status | Cheerful; follows conversation better with the hearing aids |
| Gait | Steady |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be found | resolved | confirmed | R41.3 | S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age. |
| Alzheimer's disease with early onset, confirmed by a positive amyloid PET, with an amnestic presentation; traumatic encephalopathy syndrome, a research diagnosis, considered | active | confirmed | G30.0 | S — Synthetic modern diagnosis by current criteria at the third visit; not a retrospective diagnosis of the historical person beyond the documented Alzheimer's disease. |
| Mild dementia due to Alzheimer's disease (CDR 1, MMSE 22, MoCA 18), without behavioral or psychological symptoms | active | confirmed | F02.A0 | S — Synthetic stage at diagnosis. |
| Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylurea | active | confirmed | E11.9 | S — Synthetic modern diabetes anchored to his documented diabetes. |
| Hypertension, controlled on lisinopril | active | confirmed | I10 | S — Synthetic modern hypertension anchored to the single press report. |
| Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometry | active | confirmed | H90.3 | S — Synthetic finding checked as a modifiable contributor to cognitive difficulty. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA, MMSE) | At diagnosis, then yearly, or sooner with change | Up to date | Next in a year |
| Medication safety | Medicine review for anticholinergic and sedating drugs (Beers) | Every visit | Completed today | No anticholinergic or sedating drugs |
| Survey | Behavioral and psychological symptoms (NPI-Q items) | Every visit | Completed today | None |
| Medication safety | Cholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulse | Each follow-up and each dose change | Completed today | Five weeks on 5 mg without side effects; pulse 64; raised to 10 mg today |
| Self-management | Driving, firearm and home safety | At diagnosis and each follow-up | Completed today | Not driving; no firearm in the home; stove shut-off fitted |
| Self-management | Care partner support and burden (Zarit, narrative) | At diagnosis, then at least yearly | Completed today | Adult day program two days a week; caregiver class started |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Up to date | Completed at the preventive visit two weeks ago |
| Laboratory | Hemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia review | Every three months after a therapy change; every six months when stable | Completed today | 6.9%, from 6.4%, off glipizide; no low readings |
| Examination | Blood pressure, goal under 130/80 mmHg | Every visit | Completed today | 128/76 mmHg |
| Laboratory | Potassium and creatinine on lisinopril and metformin | Yearly, and after acute illness or dehydration | Up to date | Normal at intake |
| Examination | Dilated diabetic eye examination | Every one to two years without retinopathy | Deferred | The dilated eye examination requested at intake was missed because he no longer drives and the appointment was forgotten on the morning. No harm is known: he has no visual symptoms and his diabetes is well controlled, but retinopathy cannot be excluded until he is examined. Corrective action: re-booked with paratransit, a same-morning reminder call to his care partner, and the appointment added to the day program's calendar |
| Self-management | Exercise and social activity | Every visit | Completed today | Day program exercise group and daily walks |
Goal progress:
Immunizations given today: Tdap vaccine, deferred from the preventive visit at his request [S]
Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); 13. Older Adults: Standards of Care in Diabetes-2026 (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Practice Parameter update: Evaluation and management of driving risk in dementia (2010); Adult Immunization Schedule by Age (2026)
Follow-up: Tdap given today. Eye examination as re-booked. Sixteen-week review in five weeks. Call for side effects of the higher donepezil dose. Next scheduled visit 1984-10-27: sixteen-week review: medicines, kidneys, mood, caregiver strain and the plan. [S]